Eupraxia Pharmaceuticals Inc., a Canadian-based pharmaceutical company, has submitted a report to the U.S. Securities and Exchange Commission (SEC) today, as per the requirements for foreign private issuers. The filing, known as a Form 6-K, indicates the company's compliance with the SEC's reporting standards for the month of July 2024.
In the report, Eupraxia Pharmaceuticals, which is listed under the pharmaceutical preparations industry with a standard industrial classification code of 2834, included a press release dated today. The press release is part of the documentation filed with the SEC. The company, headquartered in Victoria, British Columbia, operates under the organization name 03 Life Sciences.
The filing did not disclose any specific financial data or operational results. It is a routine disclosure that publicly-traded companies, including foreign entities like Eupraxia Pharmaceuticals that are listed on U.S. exchanges, must file periodically. The company's fiscal year-end is noted as December 31.
Eupraxia Pharmaceuticals has designated Bruce Cousins, the President and Chief Financial Officer of the company, as the authorized signatory for this SEC submission. The business address and contact information for Eupraxia Pharmaceuticals remain the same as previously reported, with no changes in location or telephone number.
This SEC filing ensures that Eupraxia Pharmaceuticals maintains transparency with its investors and complies with international regulatory requirements. The company files annual reports under Form 40-F, as indicated in the report, which is the format used by Canadian issuers that are permitted to file under the Multi-Jurisdictional Disclosure System (MJDS) developed between the United States and Canada.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.